000			01838 a2200517 4500
005			20250517015401.0
264		0	_c20150910
008			201509s 0 0 eng d
022			_a1542-6270
024	7		_a10.1177/1060028015570729 _2doi
040			_aNLM _beng _cNLM
100	1		_aKlibanov, Olga M
245	0	0	_aOmbitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. _h[electronic resource]
260			_bThe Annals of pharmacotherapy _cMay 2015
300			_a566-81 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_a2-Naphthylamine
650	0	4	_aAnilides _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aClinical Trials, Phase I as Topic
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aCyclopropanes
650	0	4	_aDrug Combinations
650	0	4	_aDrug Resistance, Viral
650	0	4	_aDrug Therapy, Combination
650	0	4	_aGenotype
650	0	4	_aHepacivirus _xgenetics
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHumans
650	0	4	_aLactams, Macrocyclic
650	0	4	_aLiver Cirrhosis _xdrug therapy
650	0	4	_aMacrocyclic Compounds _xtherapeutic use
650	0	4	_aProline _xanalogs & derivatives
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aRitonavir _xtherapeutic use
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aTablets
650	0	4	_aUracil _xanalogs & derivatives
650	0	4	_aValine
700	1		_aGale, Stormi E
700	1		_aSantevecchi, Barbara
773	0		_tThe Annals of pharmacotherapy _gvol. 49 _gno. 5 _gp. 566-81
856	4	0	_uhttps://doi.org/10.1177/1060028015570729 _zAvailable from publisher's website
999			_c24622459 _d24622459